ArticleMedicine2026
Association of D-dimer, fibrin degradation products, and coagulation parameters with progressive hemorrhagic injury following traumatic brain injury: A retrospective cohort study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
This study aimed to evaluate the predictive value of coagulation biomarkers, particularly D-dimer and fibrin degradation products (FDP), in the development of secondary progressive hemorrhagic injury (PHI) following traumatic brain injury (TBI). We conducted a retrospective cohort study based on hospital medical record data. All enrolled TBI patients were divided into a PHI group (n = 51) and a non-PHI group (n = 151) for comparison based on whether PHI occurred during hospitalization. Comprehensive coagulation profiles, including D-dimer, FDP, Prothrombin time, thrombin time, fibrinogen (FIB), and activated partial thromboplastin time (APTT), were analyzed. Multivariate logistic regression was performed to identify independent risk factors. The incidence of PHI was 25.25% (51/202). PHI patients demonstrated significantly higher systolic blood pressure (154.00 mm Hg vs 139.00 mm Hg, P = .002) and longer hospital stays (20.00 days vs 13.00 days, P = .007). Coagulation analysis revealed lower FIB (2.75 g/L vs 3.04 g/L, P = .021) and APTT (28.90 seconds vs 29.90 seconds, P = .048), but markedly elevated D-dimer (9162.00 ng/mL vs 3191.00 ng/mL, P = .001) and FDP levels (73.77 μg/mL vs 22.19 μg/mL, P = .003) in the PHI group. Logistic regression identified Glasgow Coma Scale score as an independent risk factor [adjusted odds ratio = 1.558, 95% confidence interval = 1.056-2.298, P = .025] and APTT as a protective factor (odds ratio = 0.937, 95% confidence interval = 0.915-0.959, P < .001) of secondary PHI in patients with TBI. Coagulation dysfunction, characterized by elevated D-dimer and FDP and decreased FIB, was significantly associated with PHI development in TBI patients. Multivariable logistic regression revealed that only Glasgow Coma Scale score and APTT remained significant and were independent predictors of secondary PHI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.